Treatment with an ATX inhibitor (BMP22) of mice harboring pre-established bone metastases from the ATX-null MDA-BO2 breast cancer cells significantly reduced the progression of osteolytic lesions [80,81]. Here, ENPP2 is linked to breast cancer.